Development and characterization of mouse monoclonal antibodies targeting to distinct epitopes of Zika virus envelope protein for specific detection of Zika virus

Abstract

The recent Zika virus (ZIKV) epidemic poses a serious threat to global health due to its association with microcephaly and congenital diseases in newborns and neurological complications and Guillain-Barré syndrome in adults. However, the majority of people infected with ZIKV do not develop symptoms. The platforms aimed to specifically diagnose ZIKV infection are needed for patient care and public health surveillance. In the study, four ZIKV envelope (E) protein-specific monoclonal antibodies (mAbs) (A1, B1, C1, and 9E-1) have been developed by using the conventional mAb technology. The binding epitopes of mAbs A1, B1, C1, and 9E-1 are located at E(238-257), E(410-431), E(258-277), and E(340-356), respectively. mAb 9E-1 performs 1.4to 47-fold strong affinity to ZIKV E protein compared to another three mAbs. mAbs A1, C1, and 9E-1 do not have crossreactivity against the recombinant E proteins of dengue virus serotypes 2, 3, and 4. Although these four mAbs do not have ZIKV neutralizing activity, mAbs B1 and 9E-1 have been developed as the lateral flow immunochromatographic assay for specific detection of ZIKV E protein and virions. Key points• The mAbs targeting to the regions of E(238-257), E(410-431), E(258-277), and E(340-356) do not have ZIKV neutralizing activity.• The binding epitope of mAb 9E-1 is highly specific to ZIKV E protein.• mAbs B1 and 9E-1 can bind to ZIKV virions and have been developed as the lateral flow immunochromatographic assay.

Co-infection of dengue and Zika viruses mutually enhances viral replication in the mosquito Aedes aegypti

“…Though it is not clear whether co-infected patients develop more severe disease [ 39 – 42 ], increased co-circulation and transmission of multiple flaviviruses will surely pose significant problems for diagnosis and surveillance because of the common clinical presentation, asymptomatic response, and cross-reactivity. Although progress is being made on the diagnostics front [ 43 – 45 ], effective vector control remains the most effective approach to managing and eliminating mosquito-borne diseases [ 3 ]. Central to vector control is a clear understanding of the pathogen-vector relationship as it evolves in real-time, with expanding arboviral co-circulation being a worrying trend that we have addressed.…”

Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion

“…2A , viii). To be noted, S2-10H showed no inhibition of syncytium, like the isotype control antibody ZIKV-A1 ( 30 ) ( Fig. 2A , iii and iv).…”

Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain

“…The pseudotyped lentivirus containing with the cell-surface expressed SARS-CoV-2 S protein and the internal EGFP or luciferase reporter gene was utilized to examine whether 7 Eb-4G and 1Ba–3H can inhibit the pseudotyped virus infection in ACE2-293T cells. The results showed that the isotype control antibody ZIKV-B1( Li et al, 2021 ) and 7 Eb-4G did not have any neutralizing activity since the EGFP was successfully expressed upon pseudotyped virus infection in ACE2-293T cells ( Fig. 3 A).…”